Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Delinia

Delinia

Delinia is a biotechnology company that is developing novel therapeutics for treating autoimmune diseases.

Delinia is a biotechnology company that is developing novel therapeutics for treating autoimmune diseases. The lead novel therapeutics of Delinia provides treatment to potentiate and expand regulatory T cells and immune cells that are important to maintaining self-tolerance and immune system homeostasis. The treatment works with the potential to selectively treat immune disorders without suppressing a patient’s immune system.

Delinia is creating novel therapeutics that rebalance the immune system for treating serious and life-threatening autoimmune diseases. Delinia has a novel protein therapeutic platform that is built on technology which was created by co-founder and Chief Scientific Officer, Jeffrey Greve PhD.

Its platform targets, activates, and augments the levels of Tregs, a cell type that exists naturally in the body and whose function is to regulate the inflammatory response of other cells.

Delinia has been acquired by Celgene Corporation.

Timeline

September 14, 2016
Delinia raises a $35,000,000 series A round from Sofinnova Partners.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

References

Golden logo
By using this site, you agree to our Terms & Conditions.